DISCLAIMER & DISCLOSURE: James Emanuel has no position in Judges Scientific, but Chris Waller does. This information is accurate at the time of publication, but that may change. The views expressed are those of the author at the time of publication and may change without notice. The author has no duty or obligation to update this information. Some content is sourced from third parties believed to be reliable, but accuracy is not guaranteed. Forward-looking statements involve assumptions, risks, and uncertainties, meaning actual outcomes may differ from those envisaged in this analysis. Past performance is not indicative of future results. All investments carry risk, including financial loss. This analysis is for educational purposes only and does not constitute investment advice or recommendations of any kind. Conduct your own research and seek professional advice before investing.
Acquisition-as-a-Business (AaaB)
This is now the eighth post in the ‘AaaB’ series. If you missed the others, here are the links:
Relais Group investment analysis
Fairfax India (podcast/video presentation)
Topicus - Part 2 - How to value Topicus
This Judges Sceintic (podcast)
Fairfax India analysis to compliment (4) above
Judges Scientific Plc (JDG.L), listed on the UK Alternative Investment Market of the London Stock Exchange, has built its entire identity around one thing: a disciplined and highly effective buy-and-build strategy. Over the years, that strategy has turned the company into a respected specialist in high-end, niche scientific instruments: pieces of mission-critical kit used by universities, research labs, manufacturers and regulators around the world.
Since its founding in 2002 and its first acquisition in 2005, Judges has become one of the most successful consolidators in a fragmented industry, compounding at 35% CAGR (compound annual growth rate) over two decades to its peak valuation.
It targets high-quality businesses with dependable sales, profits and cash flow, and once they’re brought into the group, they benefit from steady operational support and the financial stability of a larger organisation.
Below are the portfolio companies that Judges Scientific has acquired over the years.
The cash generation of these subsidiaries is utilized to pay down debt and fund the next round of acquisitions. It’s a flywheel that has been spinning for two decades, and despite a recent draw down in the share price, it has still delivered an impressive 24% CAGR.
The last 18 months have tested that model in ways investors haven’t seen for years. The share price has fallen more than 50%, not because the strategy has failed, but because several challenges arrived all at once.
First, the company’s valuation had simply run too hot. After years of near-flawless execution, the stock was priced for perfection, and that left no room for disappointment. The disappointment came in the form of a major acquisition that didn’t perform as expected in its first year, triggering a profits warning and shaking confidence.
Then came external pressures. China shifted its procurement policies in favour of domestic suppliers, creating an abrupt slowdown in demand for Judges’ instruments. Meanwhile, in the US, delays and cuts in federal research budgets put pressure on university spending, squeezing order flow from another key region.
And layered on top of all of this was the news that long-standing CEO and founder David Cicurel will step down in February 2026. Any leadership transition naturally results in uncertainty and anxiety among investors.
Taken together, it was a perfect storm.
Yet storms pass, and in Judges’ case, many of the clouds already appear to be clearing. The valuation multiple is now roughly half its peak, creating a far more reasonable starting point for new investors. The large acquisition that stumbled out of the gate is showing clear signs of recovery in its second year. Chinese demand is beginning to rebound, and US university funding conditions are improving. More particularly, the succession plan looks solid: Cicurel will move into the role of Non-Executive Chairman, while incoming CEO Dr Tim Prestidge, currently Group Business Development Director, offers continuity rather than disruption.
Crucially, the earnings power of the business hasn’t deteriorated. If anything, the cadence of acquisitions means its long-term potential is stronger than ever. For some investors, the recent sell-off may look less like a red flag and more like an opportunity.
Judges Scientific remains a business with a proven model, a strong culture and a two-decade track record of compounding growth. To dive deeper into the company’s history, challenges and prospects, enjoy this podcast conversation with Chris Waller of Plural Investing, author of the Hidden Gems Substack and a former Goldman Sachs Asset Management professional with an MBA from Columbia Business School.
